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Background:  The  Advisory  Committee  on  Immunization  Practices  recommends  routine  childhood  vac-
cination  by  age  2  years,  yet evidence  suggests  that only  2%  to 26%  of children  receive  vaccine  doses  at
age-appropriate  times  (compliance).  The  objective  of  this  study  was  to  estimate  vaccine  completion  and
compliance  rates  between  birth  and  age  2 years  using  recent,  nationally  representative  data.
Methods:  Using  a sample  of  children  aged  24  to  35  months  from  the  2012  National  Immunization  Survey
(NIS),  the  present  study  examined  completion  and  compliance  of  recommended  childhood  vaccines.  A
state-speciﬁc  examination  of vaccine  completion  and  compliance  was  also conducted.
Results:  An  unweighted  sample  of 11,710  children  (weighted  to 4.1  million)  was  selected.  Approximately
70%  of  children  completed  all doses  of six  recommended  vaccines  by  24  months  of  age.  Completion
rates  varied  by  antigen,  ranging  from  68%  completing  two  or three  doses  of  rotavirus  vaccine  to  92%
completing  three  doses  of  inactivated  poliovirus  vaccine.  Vaccine  completion  rates  also  varied  at  different
measurement  periods,  with  the  lowest  rates  observed  at 18  months.  Approximately  26%  of  children
received  all  doses  of six  recommended  vaccines  on  time.  Among  the 74% of  children  who  received  at
least  one  late  dose,  39% had  >7  months  of  undervaccination.  Patterns  of  completion  and  compliance  also
varied  by  geographic  region.
Conclusions:  Completion  of individual  antigens  approached  Healthy  People  2020  targets.  However,  overall
completion  of the  recommended  vaccine  series  and  compliance  with  the  recommended  vaccination
dosing  schedule  were  low,  indicating  few children  received  vaccines  at  age-appropriate  times.  Additional
clinical,  policy,  and  educational  interventions  are  needed  to increase  receipt  of vaccines  at optimal  ages.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
The Advisory Committee on Immunization Practices (ACIP)
ecommends children receive multiple vaccinations between birth
nd age 2 years to protect against 14 diseases [1]. The recom-
ended series includes completion of four doses of diphtheria,
etanus, and acellular pertussis vaccine (DTaP); three doses of
nactivated poliovirus vaccine (IPV); one dose of measles, mumps,
Abbreviations: ACIP, Advisory Committee on Immunization Practices; DTap,
iphtheria, tetanus, and acellular pertussis vaccine; HepA, hepatitis A vaccine; HepB,
epatitis B vaccine; Hib, Haemophilus inﬂuenzae type b vaccine; IIS, immuniza-
ion information systems; IPV, inactivated poliovirus; MMR,  measles, mumps, and
ubella vaccine; NIS, national immunization survey; PCV, pneumococcal conjugate
accine; SCHIP, State Children’s Health Insurance Program; US, United States.
∗ Corresponding author. Tel.: +1 919 541 7164; fax: +1 919 541 7222.
E-mail addresses: skurosky@rti.org (S.K. Kurosky), kldavis@rti.org (K.L. Davis),
irishanthy.x.krishnarajah@gsk.com (G. Krishnarajah).
ttp://dx.doi.org/10.1016/j.vaccine.2015.11.011
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
and rubella vaccine (MMR); three or four doses of Haemophilus
inﬂuenzae type b vaccine (Hib); three doses of hepatitis B vaccine
(HepB); one dose of varicella vaccine; and four doses of pneumococ-
cal conjugate vaccine (PCV) (i.e., 4:3:1:3:3:1:4). Additionally, the
ACIP recommends receipt of two  or three doses of rotavirus vac-
cine, one or two  doses of inﬂuenza vaccine; and at least one dose
of hepatitis A vaccine (HepA) by age 2 years.
Evidence suggests that appropriate vaccination coverage is
linked to improved health outcomes and cost savings [2,3]. A
decision-analytic model examining completion of the childhood
vaccination schedule in a 2009 United States (US) birth cohort
indicated prevention of approximately 42,000 early deaths and 20
million cases of disease in their lifetime. Moreover, the analyses
showed that routine vaccination may  lead to an offset of approx-
imately $69 billion in total societal costs [3]. The Healthy People
2020 Immunization and Infectious Disease goals targets 90% of
children to receive all doses of individual vaccines (i.e., DTaP, IPV,
MMR,  Hib, HepB, and varicella), 80% to receive all doses of rotavirus
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
3 accine
v
a
r
f
d
9
H
w
c
p
2
d
n
a
c
c
c
o
r
o
o
a
2
2
l
c
r
t
l
s
t
t
h
t
t
i
e
d
b
T
T
D
M
i88 S.K. Kurosky et al. / V
accine, and 80% to receive all doses in the 4:3:1:3:3:1:4 series by
ge 19 to 35 months [2].
Although, vaccination coverage has improved in the US over
ecent years, data from the National Immunization Survey (NIS)
ound approximately 68% of 2-year-old children completed all
oses in the 4:3:1:3:3:1:4 series in 2012. Furthermore, targets of
0% completion were not achieved for DTaP (83%), PCV (82%), and
epA (82%) vaccines. Similarly, receipt of rotavirus vaccine (69%)
as below the target of 80% [4].
Complying with age-appropriate receipt of vaccinations is
ritical for providing maximum effectiveness against vaccine-
reventable diseases [1]. However, prior studies indicate that only
% to 26% of 2-year-olds actually comply with the age recommen-
ations for each vaccine dose [5,6]. Although these studies provide
ovel information on vaccination rates, they were conducted
pproximately 10 years ago. As vaccination recommendations and
overage patterns have changed, recent assessments of vaccine
ompliance are needed.
In this study, we examined completion and compliance rates of
hildhood vaccinations among a nationally representative sample
f children in the US. We  assessed the proportion of children who
eceived recommended doses of vaccine by age 2 years, the number
f doses received at age-appropriate times, the cumulative number
f days undervaccinated, and geographic variations of completion
nd compliance.
. Methods
.1. Data source: National Immunization Survey
Data for this study were derived from the 2012 NIS Pub-
ic Use File [7,8]. The NIS is an annual population-based survey
onducted by the National Center for Immunization and Respi-
atory Diseases, the National Center for Health Statistics, and
he Centers for Disease Control and Prevention. It consists of a
ist-assisted random digit-dialing landline and cellular telephone
urvey (household interview) to guardians of children aged 19
o 35 months to collect demographic and vaccination informa-
ion. Immunization provider(s) reports the child’s vaccination
istory. Data were weighted to represent the greater US popula-
ion, adjusting for households with multiple telephone lines, no
elephone service, and nonresponse. Detailed NIS methods and
nstitutional review board approval for data analysis are reported
lsewhere [9,10]. RTI International’s institutional review board
etermined that this study met  all criteria for exemption (ID Num-
er 13523).
able 1
otal count of doses required to be received by 8, 18, and 24 months of age.
Vaccine No. of doses recommended by
8 months 18 m
DTaP 3 4 
IPV  2 3 
MMR  N/A 1 
Hib  2 or 3 3 or
HepB 2 3 
Varicella N/A 1 
Rotavirus 2 or 3 2 or
PCV  3 4 
4:3:1:3:3:1 series 3 DTaP, 2 IPV, 2 or 3 Hib, and 3
HepB
4 DT
Hep
4:3:1:3:3:1:4
series
3  DTaP, 2 IPV, 2 or 3 Hib, 3 HepB,
and 3 PCV
4 DT
Hep
TaP = diphtheria, tetanus, and acellular pertussis vaccine; HepB = hepatitis B vaccine; 
MR  = measles, mumps, and rubella vaccine; N/A = not applicable; PCV = pneumococca
mmunization schedule [1]. 34 (2016) 387–394
2.2. Study sample
The 2012 NIS contains information on 25,736 (unweighted sam-
ple) children aged between 19 to 35 months. From this sample,
we selected children who completed the survey, lived in the US
(excluding the US Virgin Islands), and had adequate vaccination
data supplied by their vaccine providers. Children aged less than
24 months at the time of the survey were excluded. This restriction
allowed for an equal vaccine capture period for all included chil-
dren (i.e., birth to 24 months). The ﬁnal unweighted sample size
was 11,710, equating to a weighted sample of 4,083,928 children.
2.3. Study measures
2.3.1. Vaccine completion
ACIP recommendations [1] were used to deﬁne vaccine comple-
tion at speciﬁc time points (8, 18, and 24 months of age). Vaccine
completion was  deﬁned as the accumulation of the required num-
ber of doses by a speciﬁc age irrespective of timing of vaccine
administration. For example, children receiving three doses of
DTaP, two  doses of IPV, two  or three doses of Hib, two doses of
HepB, and three doses of PCV vaccines by 8 months were consid-
ered to have completed the appropriate doses in the 4:3:1:3:3:1:4
vaccination series at that time. Rotavirus vaccine was  also assessed
at each time point. A detailed list of doses required at each time
period is presented in Table 1.
As the required number of doses of rotavirus and Hib vaccines
are dependent on the product administered, we assessed comple-
tion accordingly. For example, a child’s vaccination for rotavirus
was considered complete if two  doses of RotarixTM (GSK Vaccines)
or three doses of RotaTeq (Merck & Co., Inc.) were administered.
These algorithms are detailed in the published vaccine schedule
[1].
Although the ACIP recommends two doses of inﬂuenza vaccine
beginning at age 6 months and one dose of inﬂuenza vaccine annu-
ally thereafter, we  have not included it in this study. Inﬂuenza
vaccines should be administered prior to or during inﬂuenza sea-
son. As the NIS data only provide the child’s age at which the vaccine
was administered, we  were unable to assess whether or not the
vaccine was  given during an inﬂuenza season, which prevented
computation of accurate completion or compliance measures.
Two doses of HepA are recommended by age 2 years, with the
ﬁrst dose occurring after 12 months and the second dose occurring
6 to 18 months after the ﬁrst dose. Given the second dose may be
received outside of our observation period (birth to 24 months), we
were unable to accurately compute completion and compliance of
both doses. Therefore, HepA is not included in the present analysis.
onths 24 months
4
3
1
 4 3 or 4
3
1
 3 2 or 3
4
aP, 3 IPV, 1 MMR, 3 or 4 Hib, 3
B, and 1 varicella
4 DTaP, 3 IPV, 1 MMR, 3 or 4 Hib, 3
HepB, and 1 varicella
aP, 3 IPV, 1 MMR, 3 or 4 Hib, 3
B, 1 varicella, and 4 PCV
4 DTaP, 3 IPV, 1 MMR, 3 or 4 Hib, 3
HepB, 1 varicella, and 4 PCV
Hib = Haemophilus inﬂuenzae type b vaccine; IPV = inactivated poliovirus vaccine;
l conjugate vaccine. Source: Information derived from the CDC’s 2012 childhood
accine
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.3.2. Vaccine compliance
The ACIP recommends vaccination at speciﬁc ages and intervals
o provide maximum effectiveness and to ease scheduling through
atching the well-child visit schedule [1]. Therefore, we calculated
accine compliance as the proportion of children who received
ach dose during the ACIP’s recommended age-appropriate win-
ows (e.g., dose 1 of DTaP at 2 months) (Table 2). The ACIP allows
arly vaccination as “age-appropriate” if received within a 4-day
race period prior to the minimum age for the dose [13]. Therefore,
ny vaccines administered during this grace period were included
s on time, and any vaccines administered before this grace period
ere excluded from calculation of the compliance endpoint.
We assessed the number of days a child was  undervaccinated
sing the method proposed in several prior vaccine compliance
tudies [5,11]. A day undervaccinated was deﬁned as a day where
he child had not completed the age-appropriate doses recom-
ended by that day. This was assessed by summing the total
umber of days a delayed vaccine was given after the recom-
ended age range, per child. Each day of undervaccination was
ounted as 1 day, regardless of the number of vaccines missed
y that day [12]. If a dose was never received by 24 months,
he child received the maximum number of days undervacci-
ated based on the total number of days between the ﬁrst day of
ndervaccination and age 24 months. The ﬁnal measure of vaccine
ompliance was the total number of days undervaccinated. Accu-
ulation of 7 months or more of undervaccination was  categorizeds “severely undervaccinated”. In addition to reporting total com-
liance of each dose and series, we also assessed all doses received
n time, some doses received on time, and no doses received on
ime.
able 2
ecommended age ranges for administration by dose.
Vaccine dose Recommended age Minimum acceptable age 
DTaP
1 2 months 6 weeks 
2  4 months 10 weeks 
3  6 months 14 weeks 
4  15–18 months 12 months 
IPV
1  2 months 6 weeks 
2  4 months 10 weeks 
3  6–18 months 14 weeks 
MMR  12–15 months 12 months 
Hib
1  2 months 6 weeks 
2  4 months 10 weeks 
3  6 months 14 weeks 
4  12–15 months 12 months 
HepB
1  Birth (0–3 days) Birth 
2  1–2 months 4 weeks 
3  6–18 months 24 weeks 
Varicella 12–15 months 12 months 
Rotavirus
1  2 months 6 weeks 
2  4 months 10 weeks 
3  6 months 14 weeks 
PCV
1  2 months 6 weeks 
2  4 months 10 weeks 
3  6 months 14 weeks 
4  12–15 months 12 months 
TaP = diphtheria, tetanus, and acellular pertussis vaccine; HepB = hepatitis B vaccine; 
MR  = measles, mumps, and rubella vaccine; N/A = not applicable; PCV = pneumococcal c
ource:  Information derived from the CDC’s 2012 childhood immunization schedule [1]. 34 (2016) 387–394 389
2.4. Statistical analyses
Estimates of frequencies, percentages, means, standard errors,
and medians were calculated using SAS statistical software, ver-
sion 9.3 (SAS Institute, Inc., 2011). Survey procedures and domain
analysis techniques were used to calculate weighted values and
standard errors. To understand geographic trends of completion
and compliance, we mapped key measures by state using SAS map
procedures.
3. Results
Study sample characteristics are presented in Table 3. Of the
mothers of the sampled children, 57% were aged 30 years or older,
63% were married, 38% resided in the South, and 55% were edu-
cated beyond high school. Approximately 51% of children were
male, 47% were non-Hispanic White, and 75% had siblings in the
household. The majority of providers were based in private practice
(58%) and had one vaccine provider (66%). About half of children
were enrolled in Medicaid or the State Children’s Health Insurance
Program (SCHIP).
3.1. Vaccine completion
Table 4 describes completion rates for vaccines across at 8, 18,
and 24 months. Approximately 66% of children completed all doses
in the 4:3:1:3:3:1:4 series and 70% completed all doses in the
4:3:1:3:3:1 series by 24 months. By 24 months, the Healthy People
2020 target of 90% vaccination coverage was achieved for IPV (92%),
MMR (90%), and varicella (90%). However, rates of completion for
Recommended
interval to next dose
Age in days when
undervaccination count initiated
2 months 93
2 months 154
6–12 months 215
– 580
2 months 93
2–14 months 154
– 580
– 489
2 months 93
2 months 154
6–9 months 215
– 489
1–4 months 4
2–17 months 93
– 580
– 489
2 months 93
2 months 154
– 215
8 weeks 93
8 weeks 154
6 months 215
– 489
Hib = Haemophilus inﬂuenzae type b vaccine; IPV = inactivated poliovirus vaccine;
onjugate vaccine.
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Table  3
Background child, family, and vaccination provider characteristics.
Characteristicsa Total
n %
Unweighted sample size 11,710 100.00
Weighted sample size 4,083,928 100.00
Maternal age, years
<20 73,840 1.81
20–30 1,685,493 41.27
>30  2,324,595 56.92
Maternal marital status
Married 2,560,517 62.70
Maternal education
<High school 762,406 18.67
High school 1,092,118 26.74
>High school 952,114 23.31
College graduate 1,277,290 31.28
Census region
Northeast 657,249 16.09
South 1,566,868 38.37
Midwest 14,325 20.90
West 1,006,256 24.64
Poverty status
At or below poverty line 1,471,796 36.04
Above poverty line 2,425,133 59.38
Unknown 186,999 4.58
Number of children in household
1 1,024,197 25.08
2–3  2,446,047 59.89
>4  613,685 15.03
Child’s race/ethnicity
Non-Hispanic white 1,904,317 46.63
Non-Hispanic black 561,143 13.74
Hispanic 1,122,030 27.47
Other 496,438 12.16
Child’s sex
Male 2,064,628 50.56
Number of vaccination providers for child
0  16,779 0.41
1  2,710,147 66.36
2  1,103,784 27.03
>3  253,218 6.20
Type of vaccination providers for child
Public 497,195 12.17
Private 2,352,572 57.61
Other/mixed 1,200,295 29.39
Unknown 33,867 0.83
Had  medicaid or SCHIPb
Yes 2,032,883 49.78
SCHIP = State Children’s Health Insurance Program.
s
D
w
t
p
p
o
3
R
a
a
t
b
o
w
(
ba All percentage values will be weighted based on National Immunization Survey
ampling design.
b Less than 2% had unknown insurance status.
TaP (80%), Hib (79%), HepB (89%), PCV (80%), and rotavirus (68%)
ere below the target. Drops in completion rates were observed for
he majority of vaccines between the 8-month and 18-month time
oints. This reduction ranged from 1% (IPV) to 13% (DTaP). Com-
letion rates rose again by 24 months and were similar to those
bserved at 8 months.
.2. Vaccine compliance
Vaccine compliance varied by type of vaccine (Table 5).
ates ranged from 41% of children receiving all doses of Hib at
ge-appropriate times to 78% receiving a dose of MMR  at age-
ppropriate times. Among multi-dose vaccines, rotavirus (22%) had
he greatest proportion of children with all doses late, followed
y PCV (12%), Hib (11%), DTaP (9%), and IPV (7%). More than half
f children had at least one late dose in the Hib and PCV series,
hereas less than one-quarter of children had a late dose of IPV
24%), MMR  (22%), and varicella (22%). Examining compliance rates
y vaccination series revealed that only 23% and 26% of children 34 (2016) 387–394
received all doses in the 4:3:1:3:3:1:4 and 4:3:1:3:3:1 series on
time, respectively.
Total days undervaccinated and severe undervaccination varied
by vaccine. The mean number of days undervaccinated was  low-
est for MMR  (152 days) and varicella (154 days), and highest for
rotavirus (475 days) and PCV (258 days). Severe undervaccination
occurred more frequently for rotavirus than for any other vaccine,
with 33% of children severely undervaccinated and 42% of children
with at least one late dose. Approximately one-quarter of children
were severely undervaccinated with PCV (26%) and Hib (28%). IPV
(9%), MMR  (11%), varicella (11%), HepB (13%), and DTaP (15%) had
the lowest proportion of children with severe undervaccination.
Undervaccination of doses in the 4:3:1:3:3:1 and 4:3:1:3:3:1:4
series was, on average, 261 and 282 days, respectively, and 39%
and 43% of children were severely undervaccinated, respectively.
3.3. State-speciﬁc completion and compliance
Fig. 1 depicts vaccination completion and compliance rates in
the US (detailed in Supplemental Table 1). For the 4:3:1:3:3:1:4
series, the highest completion rates were observed for the South-
ern states (i.e., Mississippi, Tennessee, Virginia, North Carolina,
South Carolina, and Georgia) and some Midwest states (i.e., North
Dakota, Nebraska, Iowa, and Wisconsin), with Mississippi having
the highest completion rate (77%). Western states (i.e., California,
Oregon, Nevada, and Alaska) were among the states with the lowest
completion rates. Vaccine completion was lowest in Alaska (55%).
Vaccine compliance showed little variation, with the many states
in the South, Midwest, and Southwest falling in the 20% to 29%
compliance range. Compliance rates were low in some Western
states (i.e., California, Oregon, Nevada, and Alaska). Colorado (39%)
had the highest compliance rate, while Alaska (2%) had the lowest.
The majority of states had severe undervaccination rates over 40%.
Severe undervaccination was highest in Alaska (80%) and lowest in
New Hampshire (28%).
4. Discussion
Completion rates of several childhood vaccines have met
Healthy People 2020 thresholds over the past several years [4]. Con-
sistent with those estimates, we  found overall completion rates IPV,
MMR,  HepB, and varicella were approximately 90%. However, the
proportion of children receiving all vaccines in the 4:3:1:3:3:1:4
series was  low (66%).
Findings from this analysis revealed that for most of the vac-
cines, completion rates dropped between age 8 and 18 months,
then increased by 24 months. This trend is consistent with Robi-
son and colleagues [14], who found that between 11% and 21% of
children whose vaccination is complete at an interim milestone
will have incomplete vaccinations by the next milestone. This sug-
gests the current benchmarking method of assessing completion
at 2 years of age masks the true dynamic nature of immunization
status between birth and age 2 years. It is plausible that children
who are considered up-to-date at 2 years of age (or earlier mea-
surement points) may  have received vaccines too early or too late
prior to the measurement point, thus leaving them vulnerable to
vaccine-preventable diseases at earlier times. In a study of pediatric
pertussis cases over a 6-year period, researchers found that less
than half had received the DTaP immunization at age-appropriate
times [15], underlining the importance of age-appropriate vaccina-
tions for timely protection. Measuring vaccine compliance allows
us to evaluate levels of protection throughout the ﬁrst 2 years, a
time during which children are most susceptible to severe compli-
cations related to vaccine-preventable diseases.
S.K. Kurosky et al. / Vaccine 34 (2016) 387–394 391
Table  4
Vaccine completion at 8, 18, and 24 months of age.
Completion measurea 8 monthsb 18 monthsc 24 monthsd
n (%) n (%) n (%)
4 DTaP
None 179,767 4.40 128,175 3.14 111,293 2.73
All  3,360,503 82.29 2,836,117 69.45 3,286,761 80.48
3  IPV
None 193,911 4.75 150,573 3.69 136,353 3.34
All  3,744,613 91.69 3,698,565 90.56 3,766,781 92.23
1  MMR
None – – 559,212 13.69 392,365 9.61
All – – 3,524,716 86.31 3,691,564 90.39
3  or 4 Hib
None 190,159 4.66 140,135 3.43 117,924 2.89
All  3,287,144 80.49 2,949,190 72.21 3,239,905 79.33
3  Hibe
None 10,912 5.61 3,807 1.96 0 0.00
All  178,217 91.69 170,025 87.48 175,868 90.48
4  Hibf
None 61,323 1.63 18,404 0.49 0 0.00
All  3,108,927 82.43 2,779,165 73.69 3,064,037 81.24
3  HepB
None 160,286 3.92 131,355 3.22 124,516 3.05
All  3,699,946 90.60 3,569,000 87.39 3,629,710 88.88
1  Varicella
None – – 576,577 14.12 414,836 10.16
All  – – 3,507,351 85.88 3,669,093 89.84
4  PCV
None 240,999 5.90 175,469 4.30 149,926 3.67
All  3,131,998 76.69 3,073,655 75.26 3,260,475 79.84
2  or 3 Rotavirus
None 712,168 17.44 710,412 17.40 710,340 17.39
All  2,737,066 67.02 2,782,442 68.13 2,783,045 68.15
2  Rotavirusg
None 282 0.06 0 0.00 0 0.00
All  391,700 89.33 392,816 89.58 392,842 89.59
3  Rotavirush
None 1,547 0.05 72 0.00 0 0.00
All  2,345,366 79.91 2,389,626 81.42 2,390,203 81.44
4:3:1:3:3:1i
None – – – – 51,847 1.27
All  – – – – 2,855,580 69.92
4:3:1:3:3:1:4j
None – – – – 138,223 3.38
All  – – – – 2,690,038 65.87
DTaP = diphtheria, tetanus, and acellular pertussis vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus inﬂuenzae type b vaccine; IPV = inactivated poliovirus vaccine;
MMR  = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine.
a All percentage values will be weighted based on National Immunization Survey sampling design.
b Total count of doses received at 8 months includes 3 DTaP, 2 IPV, 1 or 2 Hib, 2 or 3 rotavirus, and 3 PCV.
c Total count of doses received at 18 months includes 4 DTaP, 3 IPV, 1 MMR,  3 or 4 Hib, 3 HepB, 1 varicella, 2 or 3 rotavirus, and 4 PCV.
d Total count of doses received at 24 months includes 4 DTaP, 3 IPV, 1 MMR,  3 or 4 Hib, 3 HepB, 1 varicella, 2 or 3 rotavirus, and 4 PCV.
e Among all children in the sample, 194,367 initiated the Hib series and were classiﬁed as needing to complete the 3-dose series by age 24 months.
f Among all children in the sample, 3,771,638 initiated the Hib series and were classiﬁed as needing to complete the 4-dose series by age 24 months.
g Among all children in the sample, 438,485 initiated the rotavirus series and were classiﬁed as needing to complete the 2-dose series by age 24 months.
ere cl
varice
ricella
v
o
ih Among all children in the sample, 2,935,104 initiated the rotavirus series and w
i The 4:3:1:3:3:1 series includes 4 DTaP, 3 IPV, 1 MMR,  3 or 4 Hib, 3 HepB, and 1 
j The 4:3:1:3:3:1:4 series includes 4 DTaP, 3 IPV, 1 MMR,  3 or 4 Hib, 3 HepB, 1 vaVaccine compliance has been examined in several studies with
arying methods [5–7,16,17]. Luman and colleagues [11] found
nly 9% of 19- to 35-month-old children received all vaccines
n the 4:3:1:3:3:1 series within the appropriate age ranges. Ourassiﬁed as needing to complete the 3-dose series by age 24 months.
lla recommended by age 24 months.
, and 4 PCV recommended by age 24 months.current study found that compliance for both 4:3:1:3:3:1 (26%) and
4:3:1:3:3:1:4 series (23%) was  substantially higher. Better compli-
ance rates could be attributed to an improvement in immunization
strategies over the past 15 years. Nonetheless, nearly 75% of
392 S.K. Kurosky et al. / Vaccine 34 (2016) 387–394
Table  5
Vaccine compliance for individual vaccines and series.
Compliance measurea
No. doses on time Some doses on time All doses on time Severely
undervaccinatedb
Total number of days
undervaccinatedc
n % n % n % n % Mean SE Median
4 DTaP 361,635 8.86 1,439,299 35.24 2,282,994 55.90 603,353 14.77 214.11 5.72 150.32
3  IPV 265,493 6.50 708,464 17.35 3,109,971 76.15 347,938 8.52 219.54 8.83 86.60
1  MMR 895,268 21.92 – – 3,188,661 78.08 436,786 10.70 151.88 3.38 177.71
Hib  452,587 11.08 1,938,701 47.47 1,692,640 41.45 1,139,169 27.89 228.46 4.77 163.29
3  Hibd 27,860 14.33 105,255 54.15 61,252 31.51 82,158 42.27 271.83 11.01 245.38
4  Hibe 306,804 8.13 1,833,446 48.61 1,631,388 43.25 939,088 24.90 203.20 4.66 130.96
3  HepB 343,140 8.40 1,260,679 30.87 2,480,109 60.73 523,497 12.82 220.52 6.92 111.74
1  varicella 911,465 22.32 – – 3,172,463 77.68 455,983 11.17 154.20 3.36 184.13
4  PCV 499,529 12.23 1,543,825 37.80 2,040,574 49.97 1,051,757 25.75 258.46 5.98 199.20
Rotavirus 908,736 22.25 786,135 19.25 2,389,057 58.50 1,330,680 32.58 474.58 6.87 576.92
2  Rotavirusf 30,913 7.05 71,410 16.29 336,162 76.66 47,384 10.81 287.91 25.94 74.11
3  Rotavirusg 167,483 5.71 714,725 24.35 2,052,896 69.94 572,956 19.52 364.66 10.32 504.73
4:3:1:3:3:1h 164,474 4.03 2,873,725 70.37 1,045,729 25.61 1,587,052 38.86 260.77 4.56 213.24
4:3:1:3:3:1:4i 164,474 4.03 2,993,932 73.31 925,522 22.66 1,765,117 43.22 281.88 4.65 241.21
DTaP = diphtheria, tetanus, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus inﬂuenzae type b vaccine; IPV = inactivated
poliovirus vaccine; MMR  = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; SE = standard error.
a All percentage values will be weighted based on National Immunization Survey sampling design.
b Severely undervaccinated is deﬁned as a total of 7 or more months undervaccinated.
c Total number of days undervaccinated is deﬁned as the sum of days undervaccinated for at least one vaccine.
d Among all children in the sample, 194,367 initiated the Hib series and were classiﬁed as needing to complete the 3-dose series by age 24 months.
e Among all children in the sample, 3,771,638 initiated the Hib series and were classiﬁed as needing to complete the 4-dose series by age 24 months.
f Among all children in the sample, 438,485 initiated the rotavirus series and were classiﬁed as needing to complete the 2-dose series by age 24 months.
g Among all children in the sample, 2,935,104 initiated the rotavirus series and were classiﬁed as needing to complete the 3-dose series by age 24 months.
h The 4:3:1:3:3:1 series includes 4 DTaP, 3 IPV, 1 MMR,  3 or 4 Hib, 3 HepB, and 1 varicella recommended by age 24 months.
i The 4:3:1:3:3:1:4 series includes 4 DTaP, 3 IPV, 1 MMR,  3 or 4 Hib, 3 HepB, 1 varicella, and 4 PCV recommended by age 24 months.
Fig. 1. State-speciﬁc analyses of completion and compliance rates of the 4:3:1:3:3:1:4 series.
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hildren do not receive all doses on time, providing further support
hat a large proportion of children are not adequately immunized
etween birth and 24 months. We  also found that a high propor-
ion of children were severely undervaccinated, which may  point to
ssues with accessing preventative care, vaccine delivery, or inten-
ional refusal to complete the series [5].
In the state-speciﬁc analysis, observed regional trends may  indi-
ate geographic differences in the factors impacting vaccination
ehavior and uptake. For example, Western states such as Oregon,
alifornia, Nevada, and Alaska had low completion and low com-
liance rates, indicating that children were not receiving vaccines
t all or on time. This trend may  be reﬂective of the high prevalence
f vaccine hesitancy in this region [18,19]. However, the Southern
tates such as Virginia, Tennessee, North Carolina, and South Car-
lina had among the highest completion rates in the country, yet
ompliance rates were moderate. This indicates that children were
eceiving vaccines late, but catching up with the required number
f doses by 24 months. Such a trend may  suggest issues with access
o vaccines or missed opportunities to vaccinate. In addition, vac-
ine shortages due to increased demand, delays in manufacturing
r shipping, new indications, discontinued products, or cold-chain
isruption can lead to delayed and incomplete vaccination. At the
ime of this study, the authors did not ﬁnd evidence of national vac-
ine shortages; however, unobserved shortages at the local level
ay have impacted geographic differences in vaccine completion
nd compliance.
The NIS has several limitations. The telephone survey method-
logy relies on the household respondent to identify all vaccine
roviders and for these providers to accurately report vaccination
istory. There is potential bias due to households without land-
ine or cell phone service and nonresponse. It is also possible some
roviders were not identiﬁed or that those who were identiﬁed
id not report the child’s entire vaccine history. This could result
n some children being misclassiﬁed in our study with regard to
ompletion and compliance measures. In addition, the NIS lacks
ssessment of knowledge, attitudes, beliefs, or other factors related
o vaccination that could provide a better understanding of reasons
or undervaccination. Although the NIS sample is weighted to rep-
esent the national population, sample sizes within each state are
mall and result in wide conﬁdence intervals. Other data sources,
uch as vaccine surveillance data captured in state or regional
mmunization Information Systems (IIS), include population-level
ata for a given geographic region and may  be utilized to exam-
ne local vaccine completion and compliance with a more precise
stimate for a speciﬁc geographic region or population. Future stud-
es may  consider validating NIS estimates with IIS data or other
opulation-based data sources.
. Conclusions
Despite these limitations, the NIS is a unique, publically avail-
ble dataset that tracks childhood vaccinations at the state and
ational level; therefore, it is an important source for measur-
ng vaccination completion and compliance. Our study evaluates
 recent cycle of the NIS, adding to the literature on estimating vac-
ination trends. Our ﬁndings indicated that although completion
ates were relatively high, a large proportion of children remained
ndervaccinated for some period before age 2 years, leaving them
t risk during a vulnerable period in life. Although vaccine compli-
nce rates improved over the past decade, rates remain low, as only
 quarter of children received all age-appropriate vaccinations. As
he recommended vaccine schedule is built on evidence of vaccine
ffectiveness and synchronization with the standard well-child
isit schedule, the lack of vaccine compliance may signify underuti-
ization of other preventative care (e.g., developmental milestone 34 (2016) 387–394 393
assessments). Future research quantifying the impact of missed
well-child visits, opportunities for vaccination, and other preven-
tative health interventions should be explored. Use of automated
clinical decision support tools, vaccine forecasters, and reminder-
recall systems may  be integrated into local IIS or medical record
systems as they are effective, evidence-based methods for increas-
ing vaccination rates [20]. Programs such as home nurse visits, the
Vaccines for Children program, local school and childcare immu-
nization policy, and integration of vaccine forecasting in alternative
settings (e.g., Women, Infant, and Children programs) enhancing
access to vaccines, which may  result in improved vaccination rates.
Sustained efforts involving educational, clinical, and policy inter-
ventions should continue to reach optimum vaccination levels as
recommended by the ACIP.
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